WeForNews | Latest News, Breaking News, News Updates Remdesivir linked to reduced death risk in severe Covid-19 patients | WeForNews | Latest News, Blogs
Connect with us

Disaster

Remdesivir linked to reduced death risk in severe Covid-19 patients

The mortality rate for patients treated with remdesivir in the analysis was 7.6 per cent at Day 14 compared with 12.5 per cent among patients not taking remdesivir.

Published

on

remdesivir antiviral drug

New York, July 11 : New data revealed by Gilead Sciences has shown that its antiviral drug remdesivir reduces death risk of severe Covid-19 patients by as much as 62 per cent when compared with standard care alone.

This is an important finding that requires confirmation in prospective clinical trials, Gilead said on Friday about the results presented at the virtual COVID-19 conference as part of the 23rd International AIDS Conference.

The analysis included 312 patients treated in the Phase-3 SIMPLE-Severe study and a separate real-world retrospective cohort of 818 patients with similar baseline characteristics and disease severity who received standard of care treatment in the same time period as the SIMPLE-Severe study.

Patients were primarily located in North America (92 per cent, remdesivir cohort vs. 91 per cent, standard-of-care cohort), Europe (5 per cent vs. 7 per cent) and Asia (3 per cent vs. 2 per cent).

The analysis demonstrated that remdesivir treatment was associated with significantly improved clinical recovery and a 62 percent reduction in the risk of mortality compared to standard of care.

Findings from the comparative analysis showed that 74.4 per cent of remdesivir-treated patients recovered by Day 14 versus 59 per cent of patients receiving standard of care.

The mortality rate for patients treated with remdesivir in the analysis was 7.6 per cent at Day 14 compared with 12.5 per cent among patients not taking remdesivir.

“This comparative analysis provides valuable additional information regarding the benefit of remdesivir compared with standard of care alone,” Susan Olender of Columbia University Irving Medical Center said in a statement.

“While not as vigorous as a randomized controlled trial, this analysis importantly draws from a real-world setting and serves as an important adjunct to clinical trial data, adding to our collective understanding of this virus and reflecting the extraordinary pace of the ongoing pandemic.”

The results of this comparative analysis add to the previously presented National Institute of Allergy and Infectious Disease (NIAID) randomized, double-blind, placebo-controlled study in hospitalized patients with COVID-19, which showed that remdesivir shortened time to recovery by an average of four days as compared to placebo — 11 vs. 15 days.

In the NIAID study, patients taking remdesivir trended toward lower mortality compared with those in the placebo group, but this result did not reach statistical significance –7.1 percent vs. 11.9 per cent.

Due to the current public health emergency, the US Food and Drug Administration (FDA) has issued an Emergency Use Authorization for remdesivir for the treatment of hospitalised patients with severe Covid-19.

“These data presented at the Virtual COVID-19 Conference shed additional light on the use of remdesivir in specific patient populations, including those that may be susceptible to higher rates of COVID-19 infection, as well as others that are particularly vulnerable, including children and pregnant and postpartum women,” said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences.

Cities

Earthquake of magnitude 4.1 strikes Jammu and Kashmir

They said while the tremors caused panic among people, there were no reports of any loss of life or injury or damage to property.

Published

on

Earthquake Strong

Srinagar, Jan 16 : An earthquake of magnitude 4.1 hit Jammu and Kashmir on Saturday, but there was no report of any damage, officials said.

At 10:01 pm, the earthquake struck at a latitude of 33.03 degrees north and a longitude of 75.93 degrees east — 93 kms east of Katra, they added.

The depth of the earthquake was 10 kms, the officials said.

They said while the tremors caused panic among people, there were no reports of any loss of life or injury or damage to property.

Continue Reading

Blog

Covaxin consent form says vax administered without ph-3 trial

The vaccine is first offered to the healthcare workers, frontline workers and those above 50 years of age, followed by the below-50 population with comorbidities, and finally to the remaining population based on disease epidemiology and vaccine availability.

Published

on

By

COVAXIN Corona Covid vaccine

New Delhi, Jan 16 : Amid the vaccinaton drive against Covid-19, it has emerged that there is a separate consent form for those who are administered the ‘Covaxin‘ vaccine manufactured by Bharat Biotech.

The form says that “In phase-1 and phase-2 clinical trial ‘Covaxin’ has demonstrated the ability to produce antibodies against Covid-19, however the clinical efficacy of Covaxin is yet to be established and it is still being studied in phase-3 clinical trial, hence it is important to appreciate that receiving the vaccine does not mean that the other precautions related to Covid-19 should not be followed.”

The form says that in case of any adverse and serious condition, the receiver will be provided utmost care at the health centre and in case of casuality the compensation will be provided by Bharat Biotech.

“The compensation for serious adverse event will be paid by sponsor BBIL if the SAE is proven to be casually related to the vaccine,” it said.

Serious concerns were raised in certain quarters including by opposition parties and Congress leader Manish Tewari has questioned the efficacy of ‘Covaxin’ while the Prime Minister has warned people not to believe in “rumours”.

The world’s biggest vaccination drive come almost a year after the first coronavirus case was detected in India, and since then the deadly virus has claimed over 1.5 lakh lives and infected one crore people. The first case came to the fore on January 30, 2020 in Kerala.

Two vaccines — the Oxford vaccine ‘Covishield’ manufactured by the Serum Institute of India, and indigenously developed ‘Covaxin’ by Bharat Biotech — will be administered to priority groups. So far, the central government has procured 1.1 crore Covishield and 55 lakh Covaxin vaccines at a cost of Rs 200 and Rs 206 per dose, respectively.

In Delhi, which has 81 vaccination sites, ‘Covaxin’ has been allotted to six Centre-run hospitals while 75 Delhi government and private hospitals will receive ‘Covishield’.

The vaccine is first offered to the healthcare workers, frontline workers and those above 50 years of age, followed by the below-50 population with comorbidities, and finally to the remaining population based on disease epidemiology and vaccine availability.

Continue Reading

Disaster

Magnitude 6.7 Earthquake Hits Russia-Mongolia Border Region

The quake was at a depth of 10 kilometers

Published

on

Earthquake Strong

AN earthquake of magnitude 6.7 struck the Russia-Mongolia Border Region on Tuesday, the GFZ German Research Center for Geosciences said.

The quake was at a depth of 10 kilometers, it added.

The epicenter of the earthquake was registered 277 kilometers southwest of the city of Angarsk, in the Russian Irkutsk region, and 30 kilometers from the Mongolian city of Turt, Russian state-owned news agency Sputnik reported. https://bit.ly/2XtgrJs

There were no immediate reports of damage or victims, the report said.

Continue Reading
Advertisement

Most Popular